Cytiva News
-
Ribobay Pharma Boosts CRDMO Offerings With Cytiva's First FlexFactory Platform For Oligonucleotides
5/15/2024
Ribobay Pharma, a leading Chinese biopharmaceutical contract research, development, and manufacturing organization (CRDMO) and a spin-off company of General Biol (Anhui) Co., Ltd, will provide cGMP-level oligonucleotide (oligo) CRDMO services to the world using Cytiva’s first FlexFactory platform for oligo manufacturing.
-
Cytiva Strengthens Cell Line Development With CEVEC Acquisition
10/6/2022
Global life sciences leader Cytiva has acquired CEVEC Pharmaceuticals, a leading German provider of high-performance cell line development and viral vector manufacturing technologies. CEVEC will further strengthen Cytiva's leading position in biomanufacturing solutions.
-
Cytiva Expanding US Operations
7/13/2022
The new chromatography resins manufacturing site is part of Cytiva and Pall Corporation’s 1.5 billion USD capacity expansion investment.
-
Cytiva To provide Arranta Bio 'Idea To Injection' solutions For integrated Manufacturing Of mRNA Products
1/25/2022
Cytiva, a global life sciences leader, will provide its FlexFactory single-use manufacturing platform to Arranta Bio ("Arranta"), a leading contract development and manufacturing organization (CDMO) for use in manufacturing mRNA vaccines.
-
Cytiva Attains Business Continuity Management System ISO Certification
1/11/2022
The new ISO 22301:2019 certification covers methods and procedures for maintaining emergency response, crisis management, and business continuity capabilities, including communication, implementation, and continual improvement.
-
Cytiva Acquires GoSilico To Strengthen Digital Capabilities In Bioprocessing
6/2/2021
Global life sciences leader Cytiva has acquired the German scientific software maker GoSilico, in a move that will differentiate Cytiva as a premier partner in bioprocessing.
-
Cytiva Provides Akron Biotech With FlexFactory For The Manufacture Of Plasmid DNA
10/15/2020
Cytiva, a global life sciences leader, will provide its FlexFactory to Akron Biotech, a leading provider of cGMP-compliant solutions to support advanced therapy development.
-
Cytiva's Fibro PrismA Technology Accelerates mAb Purification In LifeArc's Covid-19 Research
10/8/2020
Cytiva, a global life sciences leader, made Fibro PrismA, the first product based on its new protein A fiber chromatography technology, available commercially earlier this year. The new technology is already accelerating research for customers and collaborators, such as LifeArc.
-
GE Healthcare Life Sciences Joins Children's Medical Research Institute To Optimize Gene Therapy Manufacturing
2/5/2020
GE Healthcare Life Sciences and Children’s Medical Research Institute will jointly drive the development of new affinity ligands for the purification of adeno-associated viral (AAV) vectors used in gene therapies.
-
GE Healthcare Life Sciences Plans New Manufacturing Facility In Switzerland
1/22/2020
GE Healthcare Life Sciences is building a new 7,360 square meter facility in Grens, Switzerland, in the new Signy Park, for the manufacture of single use kits for the Sepax and Sefia cell processing systems. The facility will meet global regulatory requirements and is expected to be fully operational in 2022.